Johnson & Johnson (JNJ): Our Calculation of Intrinsic Value

Key Takeaways

• Intrinsic share value estimated at $165‑170, below $240 market price.
• DCF model uses 8% discount rate, 3% terminal growth.
• Net debt stands at $27.8 B, equity value $400.3 B.
• Post‑spin‑off focus on pharma and med‑tech boosts margins.
• Aging populations drive long‑term demand for J&J’s healthcare portfolio.

Pulse Analysis

Johnson & Johnson remains one of the most diversified players in global healthcare, spanning pharmaceuticals, medical devices, and innovative medicine. The recent spin‑off of its consumer‑health arm, Kenvue, has sharpened the company’s focus on higher‑margin segments, allowing it to leverage a trusted brand, extensive R&D pipelines, and a worldwide distribution network. These structural strengths position J&J as a defensive stalwart, especially as aging demographics and rising healthcare spending fuel demand for its oncology, immunology, and med‑tech offerings.

The DCF analysis applied an 8% discount rate and a 3% perpetual growth assumption, projecting free cash flow to climb to $24.3 billion by 2030. This yields an enterprise value of $428.1 billion and, after accounting for $27.8 billion of net debt, an equity valuation of roughly $400 billion, or $165‑170 per share. With the stock trading near $240, the model indicates a roughly 30% margin of safety shortfall, suggesting the market is pricing in growth or multiple expansion beyond the conservative assumptions. Investors relying on intrinsic value metrics may view the current premium as a red flag, especially given the company’s modest dividend yield relative to its valuation.

Beyond pure valuation, J&J’s defensive attributes—steady cash flow, a robust dividend, and a pipeline of high‑margin drugs—still offer appeal in volatile markets. However, the overvaluation risk underscores the importance of monitoring earnings growth, pipeline milestones, and potential regulatory headwinds. As healthcare spending continues to rise, the firm’s long‑term fundamentals remain solid, but short‑term investors should weigh the price premium against realistic growth expectations before increasing exposure.